Up­dat­ed In­cyte com­bo da­ta for epaca­do­stat/Keytru­da look promis­ing

In­cyte this morn­ing teed up a fresh look at da­ta from its ear­ly-stage study of its close­ly watched IDO1 drug epaca­do­stat com­bined with Mer­ck’s PD-1 check­point ther­a­py Keytru­da. And the up­date — a lit­tle more than week af­ter the first pre­lim­i­nary da­ta were re­port­ed — is en­cour­ag­ing some an­a­lysts to an­tic­i­pate a suc­cess for its piv­otal tri­al of the im­munother­a­py duo, which is now un­der­way.

In the lead up to the big ES­MO meet­ing this week­end, in­ves­ti­ga­tors for In­cyte $IN­CY say that they tracked pro­gres­sion-free sur­vival rates of 74 per­cent and 57 per­cent af­ter 6 months and 12 months. The study has not yet ma­tured enough for the re­searchers to pin down a me­di­an PFS rate. But the com­plete re­sponse rate has in­creased slight­ly to 26%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.